Videos and Podcasts
PXS announces positive interim data from myelofibrosis trial
Pharmaxis Ltd (ASX: PXS) held an online investor briefing by chief executive officer Mr Gary Phillips on October 19 2022.
The event consisted of an analysis of data from patients who have completed 6 months’ treatment with PXS-5505 in its Phase 2 clinical trial in patients with the bone marrow cancer myelofibrosis. Followed by a Q&A session from attendees. You can watch a recording of the presentation here.
The presentation slides are available in full here.
Pharmaxis Releases Promising Interim Data from Skin Scarring Study
Pharmaxis has released promising interim data from the clinical trial of its topical anti scarring drug PXS-6302 being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM. The study aims to improve the appearance and function of established scars by tackling the enzyme that plays a critical role in crosslinking collagen fibres in scar formation.
Watch an interview with CEO Gary Phillips outlining the study data here.
Watch the Channel Nine News story here
Watch the online investor briefing by chief executive officer Mr Gary Phillips on September 26 2022 here.
Pharmaxis Quarterly Investor Update- 29 July 2022.
Pharmaxis Ltd (ASX: PXS) released its Quarterly Shareholder Update on the morning of 29 July 2022.
Investors and analysts joined the Company for a virtual investor briefing by chief executive officer Mr Gary Phillips.
The event consisted of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees. You can watch a recording of the presentation here.